Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLI1 | P08151 | 2/20 | 0.66 |
| ▸ | SCN4A | P35499 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255493 | 1.00 | GLI1 (0.66) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL490079 | 1.00 | GLI1 (0.66) | GLI1SCN4ANOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL27654729 | 0.98 | GLI1 (0.63) | GLI1SCN4ANOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL490043 | 0.98 | GLI1 (0.63) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL28418653 | 0.98 | GLI1 (0.63) | GLI1SCN4ANOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL6387850 | 0.98 | GLI1 (0.63) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL16992331 | 0.94 | GLI1 (0.58) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL3832254 | 0.94 | GLI1 (0.58) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL2917600 | 0.94 | GLI1 (0.58) | GLI1SCN4ANOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL5430649 | 0.92 | GLI1 (0.56) | GLI1SCN4ANOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008007930-A9 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD (KR) | 2009-04-02 | — | — | WO | claimed |
| EP-2041120-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd. (KR) | 2009-04-01 | — | — | EP | claimed |
| WO-2008007930-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2008-01-17 | — | — | WO | claimed |
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | claimed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | claimed |
| EP-0316218-B1 | L-PROLINE DERIVATIVES, THEIR PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | EKITA Investments N.V. (NA) | 1993-09-15 | — | — | EP | claimed |
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| EP-0272063-B1 | MITOMYCIN DERIVATIVES | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1992-04-08 | — | — | EP | disclosed |
| US-4863935-A | Mitomycin compounds having useful anti-tumor activity | KYOWA HAKKO KOGYO K.K. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0272063-A1 | Mitomycin derivatives | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1988-06-22 | — | — | EP | disclosed |
| US-4636567-A | CNS DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1987-01-13 | — | — | US | disclosed |
| US-4610821-A | CENTRAL NERVOUS SYSTEM, THYROTROPIN RELEASING HORMONE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-09-09 | — | — | US | disclosed |
| US-4564609-A | NERVOUS SYSTEM DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0123444-A1 | 4-Substituted-2-azetidinone compound, process of producing the compounds, and medicaments containing the compounds | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | GLI1 2456/4885SCN4A 2394/4885NOS2 1937/4885 |
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | KRAS, NRAS, APC | GLI1 640/4885SCN4A 946/4885NOS2 4646/4885 |
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | GLI1 4094/4885SCN4A 3701/4885NOS2 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.